Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B known ✓ | Q13224 | 4/20 | 0.49 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.90 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753988 | 1.00 | KCNH2 (0.90) | KCNH2GRIN2BPKMHTR1ADRD2 | |
| SCHEMBL5751337 | 1.00 | KCNH2 (0.90) | KCNH2GRIN2BPKMHTR1ADRD2 | |
| SCHEMBL120402 | 0.95 | KCNH2 (1.00) | KCNH2GRIN2BHTR1ADRD2HTR2A | |
| SCHEMBL2599445 | 0.95 | KCNH2 (1.00) | KCNH2GRIN2BHTR1ADRD2HTR2A | |
| SCHEMBL877343 | 0.95 | KCNH2 (1.00) | KCNH2GRIN2BHTR1ADRD2HTR2A | |
| SCHEMBL6769022 | 0.91 | KCNH2 (0.73) | KCNH2GRIN2BPKMHTR1ADRD2 | |
| SCHEMBL6769728 | 0.86 | KCNH2 (0.80) | KCNH2GRIN2BPKMHTR1ADRD2 | |
| SCHEMBL6765758 | 0.83 | KCNH2 (0.76) | KCNH2GRIN2BALDH1A1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL6765808 | 0.83 | KCNH2 (0.75) | KCNH2GRIN2BALDH1A1OPRM1OPRD1 | |
| SCHEMBL5457660 | 0.81 | KCNH2 (0.59) | KCNH2GRIN2BALDH1A1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499606-B1 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER (US) | 2006-05-03 | — | — | EP | disclosed |
| US-6713490-B2 | 6-(2-(4-(3-FLUOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-HYDROXY -ETHYL)-3,4-DIHYDRO-2(1H)-QUINOLINONE; REDUCED INHIBITORY ACTIVITY AT HERG (HUMAN ETHER-A-GO-GO RELATED GENE) POTASSIUM CHANNEL | PFIZER, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | KAWAMURA MITSUHIRO (JP) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | GRIN3B, GRIN1, GRIN2A | GRIN2B 6/4885HTR1A 73/4885DRD2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.